16 years of historical data (2009–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Fortress Biotech, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $95M | $42M | $24M | $59M | $204M | $228M | $141M | $37M | $166M | $108M | $109M |
| Enterprise Value | $114M | $61M | $32M | $8M | $-26504500 | $84M | $119M | $51M | $119M | $48M | $34M |
| P/E Ratio → | -1.27 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 1.65 | 0.73 | 0.29 | 0.77 | 2.97 | 5.01 | 3.84 | 1.39 | 0.89 | 6.55 | 126.56 |
| P/B Ratio | — | — | 15.38 | 1.17 | 0.90 | 1.16 | 1.94 | 1.89 | 1.38 | 1.30 | 1.30 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.06 | 0.38 | 0.10 | -0.39 | 1.84 | 3.25 | 1.91 | 0.63 | 2.90 | 39.64 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Fortress Biotech, Inc. earns an operating margin of -191.4%. Operating margins have expanded from -268.8% to -191.4% over the past 3 years, signaling improving operational efficiency.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 63.8% | 63.8% | 72.9% | 59.4% | 53.4% | 68.0% | 71.2% | 77.2% | 14.1% | 31.1% | 100.0% |
| Operating Margin | -191.4% | -191.4% | -168.4% | -268.8% | -274.1% | -206.7% | -302.5% | -446.4% | -47.9% | -398.7% | -5855.3% |
| Net Profit Margin | -79.8% | -79.8% | -71.7% | -114.3% | -94.1% | -102.0% | -109.1% | -313.0% | -35.7% | -334.3% | -5611.6% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | -235.0% | -62.8% | -30.6% | -34.5% | -86.6% | -120.0% | -65.7% | -65.9% | -62.6% |
| ROA | -29.5% | -29.5% | -26.3% | -25.1% | -17.7% | -16.6% | -21.8% | -43.5% | -32.1% | -38.1% | -46.6% |
| ROIC | -629.4% | -629.4% | -2555.5% | — | -591.2% | -136.6% | -196.6% | -175.1% | -146.4% | -306.5% | -172.1% |
| ROCE | -142.0% | -142.0% | -114.2% | -88.1% | -65.3% | -40.8% | -83.3% | -92.3% | -62.2% | -59.1% | -52.3% |
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $19M ($76M total debt minus $57M cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 55.82 | 2.55 | 0.33 | 0.45 | 1.59 | 4.03 | 0.52 | 0.34 | 0.27 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | 4.83 | -1.02 | -1.02 | -0.73 | -0.30 | 0.71 | -0.39 | -0.72 | -0.89 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -11.12 | -11.12 | -11.37 | -14.92 | -12.32 | -6.15 | -9.35 | -11.61 | -11.68 | -17.81 | -34.05 |
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.27x means Fortress Biotech, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 1.80x to 1.27x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.27 | 1.27 | 1.38 | 1.80 | 3.43 | 5.14 | 3.43 | 2.00 | 2.56 | 1.94 | 9.43 |
| Quick Ratio | 1.06 | 1.06 | 1.26 | 1.69 | 3.33 | 5.11 | 3.41 | 1.99 | 2.56 | 1.93 | 9.43 |
| Cash Ratio | 0.80 | 0.80 | 0.95 | 1.40 | 3.03 | 4.51 | 3.00 | 1.49 | 2.14 | 1.62 | 9.28 |
| Asset Turnover | — | 0.40 | 0.50 | 0.26 | 0.17 | 0.14 | 0.16 | 0.19 | 0.76 | 0.10 | 0.01 |
| Inventory Turnover | 1.45 | 1.45 | 2.24 | 2.17 | 3.25 | 10.39 | 12.29 | 9.03 | 942.70 | 55.91 | — |
| Days Sales Outstanding | — | 65.83 | 66.46 | 136.60 | 126.23 | 197.49 | 143.53 | 74.65 | 29.48 | 114.88 | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Fortress Biotech, Inc. returns 1.0% to shareholders annually primarily through dividends.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 1.0% | 1.6% | 3.0% | 1.3% | 0.4% | 0.1% | 1.8% | 6.3% | 0.2% | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 1.9% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 1.0% | 1.6% | 3.0% | 3.2% | 0.4% | 0.1% | 1.8% | 6.3% | 0.2% | 0.0% | 0.0% |
| Shares Outstanding | — | $21M | $8M | $6M | $5M | $5M | $4M | $3M | $3M | $3M | $3M |
Compare FBIO with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| FBIOYou | $95M | -1.3 | — | — | 63.8% | -191.4% | — | -629.4% | — |
| REGN | $108B | 18.8 | 21.6 | 26.4 | 86.3% | 25.7% | 14.9% | 12.4% | 0.6 |
| CNTA | $4B | -13.0 | — | — | — | — | -73.9% | -91.8% | — |
| IMNM | $2B | -4.4 | — | — | 100.0% | -3382.4% | -194.6% | -700.3% | — |
| CLDX | $2B | -7.7 | — | — | 100.0% | -19160.0% | -40.6% | -35.2% | — |
| RXRX | $2B | -2.5 | — | — | 5.0% | -867.9% | -59.5% | -95.8% | — |
| NRIX | $2B | -5.2 | — | — | 77.5% | -340.2% | -49.6% | -54.0% | — |
| ROIV | $1B | -120.6 | — | — | 96.9% | -3453.3% | -3.0% | -50.4% | — |
| ABCL | $1B | -7.4 | — | — | — | -289.0% | -14.5% | -16.8% | — |
| ARVN | $975M | -10.4 | — | — | -151.8% | -45.1% | -16.2% | -23.1% | — |
| XNCR | $918M | -10.3 | — | — | — | — | -9.5% | — | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 16 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how FBIO stacks up against sector leader Regeneron Pharmaceuticals, Inc..
Start ComparisonFortress Biotech, Inc.'s current P/E ratio is -1.3x. This places it at the 50th percentile of its historical range.
Based on historical data, Fortress Biotech, Inc. is trading at a P/E of -1.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Fortress Biotech, Inc.'s current dividend yield is 0.98%.
Fortress Biotech, Inc. has 63.8% gross margin and -191.4% operating margin.